

Response to Office Action
Serial No. 09/978,454
Page 2 of 6

030727.0027.CON1

to charge trust account No. 50-1273 for the two -month extension fee due herein, and any other fees that may become due or credit become payable during the pendency of this application.

AMENDMENTS

Please amend the claims to read as follows:

E 2 169. (Once Amended) The pharmaceutical composition of claim 168, wherein MH is 9-(2-phosphonylmethoxyethyl)adenine (PMEA) or analogues thereof.

170. (Once Amended) The pharmaceutical composition of claim 168, wherein MH is 9-(2-phosphonylmethoxyethyl)adenine (PMEA).

171. (Twice Amended) The pharmaceutical composition of claim 168, wherein MH is selected from penciclovir, 3TC, ACV, PMPA, araC, ribavirin, fludarabine, and 5-fluoro-2'-deoxyuridine.

172. (Once Amended) The pharmaceutical composition of claim 168, wherein MH is radiolabelled 2'-deoxy-5-iodouridine.

173. (Once Amended) The pharmaceutical composition of claim 172 wherein MH is 2'-deoxy-5-¹³¹I-iodouridine.

174. (Once Amended) The pharmaceutical composition of claim 168, wherein V is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

175. (Once Amended) The pharmaceutical composition of claim 168, wherein the prodrug is in the *cis* configuration.

176. (Once Amended) The pharmaceutical composition of claim 174, wherein the prodrug is in the *cis* configuration.